Clinical applications of single photon emission tomography in neuromedicine

P. Bartenstein; F. Grünwald; T. Kuwert; K. Tatsch; O. Sabri; O. Benkert; R. Fahlbusch; G. Gründer; K. Herzholz; C. Weiller

doi:10.1055/s-0038-1632267

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 2000; 39(07): 180-195
DOI: 10.1055/s-0038-1632267

Original Article

Schattauer GmbH

Clinical applications of single photon emission tomography in neuromedicine

Part 1: Neuro-oncology, epilepsy, movement disorders, cerebrovascular diseaseKlinische Anwendungen der Single-Photon-Emissionstomographie in der NeuromedinTeil I: Neuroonkologie, Epilepsien, Basalganglienerkrankungen, zerebrovaskuläre Erkrankungen

Authors

P. Bartenstein

¹Arbeitsgemeinschaft Neuronuklearmedizin der Deutschen Gesellschaft für Nuklearmedizin
F. Grünwald

¹Arbeitsgemeinschaft Neuronuklearmedizin der Deutschen Gesellschaft für Nuklearmedizin
T. Kuwert

¹Arbeitsgemeinschaft Neuronuklearmedizin der Deutschen Gesellschaft für Nuklearmedizin
K. Tatsch

¹Arbeitsgemeinschaft Neuronuklearmedizin der Deutschen Gesellschaft für Nuklearmedizin
O. Sabri

¹Arbeitsgemeinschaft Neuronuklearmedizin der Deutschen Gesellschaft für Nuklearmedizin
O. Benkert

¹Arbeitsgemeinschaft Neuronuklearmedizin der Deutschen Gesellschaft für Nuklearmedizin
R. Fahlbusch

¹Arbeitsgemeinschaft Neuronuklearmedizin der Deutschen Gesellschaft für Nuklearmedizin
G. Gründer

¹Arbeitsgemeinschaft Neuronuklearmedizin der Deutschen Gesellschaft für Nuklearmedizin
K. Herzholz

¹Arbeitsgemeinschaft Neuronuklearmedizin der Deutschen Gesellschaft für Nuklearmedizin
C. Weiller

¹Arbeitsgemeinschaft Neuronuklearmedizin der Deutschen Gesellschaft für Nuklearmedizin

Abstract

Summary

Single photon emission tomography is, because of its availability and the relatively low costs, the functional imaging modality currently most widely used for clinical applications in the brain. Beside the application of radiopharmaceuticals for the assessment of regional cerebral blood flow there is an increasing clinical use of more selective SPECT-radiopharmaceuticals, like amino acid analogs or receptor ligands. This article gives in his first part a critical review of the clinical applications of SPECT in neuro-oncology, epilepsy, basal ganglia disorders and cerebrovascular disease.

Zusammenfassung

Die Single-Photon-Emissionstomographie ist wegen ihrer allgemeinen Verfügbarkeit und der relativen Kostengünstigkeit weiterhin das funktionell bildgebende Verfahren mit der größten klinischen Bedeutung für die Diagnostik von Erkrankungen des zentralen Nervensystems. Neben Radiopharmaka, die den regionalen zerebralen Blutfluss erfassen, werden zunehmend selektivere Pharmaka für klinische Fragestellungen eingesetzt, wie Aminosäurederivate oder Rezeptorliganden. Die Arbeit vermittelt in ihrem ersten Teil eine kritisch wertende Übersicht über die klinischen Anwendungsmöglichkeiten von SPECT-Untersuchungen bei Fragestellungen aus der Neuroonkologie, der Epilepsiediagnostik, bei Basalganglienerkrankungen und zerebrovaskulären Erkrankungen.

Keywords

Single photon emission tomography (SPECT) - brain tumor - epilepsy - basal ganglia - cerebrovascular

Schlüsselwörter

Single-Photon-Emissionstomographie (SPECT) - Hirntumoren - Epilepsie - Basalganglien - zerebrovaskulär

Full Text

References

Literatur
1 Alexandrov AV, Black SE, Ehrlich LE, Bladin CF, Smurawska LT, Pirisi A, Caldwell CB. Simple visual analysis of brain perfusion on HMPAO SPECT predicts early outcome in acute stroke. Stroke 1996; 27: 1537-42.
2 Alexandrov AV, Black SE, Ehrlich LE, Caldwell CB, Norris JW. Predictors of hemorrhagic transformation occuring spontaneously and on anticoagulants in patients with acute ischemic stroke. Stroke 1997; 28: 1198-202.
3 Alexandrov AV, Masdeu JC, Devous MD, Black SE, Grotta JC. Brain single-photon emission CT with HMPAO and safety of thrombolytic therapy in acute ischemic stroke. Stroke 1997; 28: 1830-4.
4 Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brücke T. [123I]beta-CIT and SPECT in essential tremor and Parkinsom’s disease. J Neural Transm 1998; 105: 1213-28.
5 Avery RA, Spencer SS, Spanaki MV, Corsi M, Seibyl JP, Zubal IG. Effect of injection time on postictal SPET perfusion changes in medically refractory epilepsy. Eur J Nucl Med 1999; 26: 830-6.
6 Awada HH, Mamo HL, Luft AG, Ponsin JC, Kahn ME. Cerebral blood flow in systemic lupus erythematosus with and without central nervous system involvement. J Neurol Neurosurg Psychiatry 1987; 50: 1597-601.
7 Bader JB, Samnick S, Moringlane JR, Feiden W, Schaefer A, Kremp S, Kirsch CM. Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med 1999; 26: 144-51.
8 Barber PA, Davis SM, Infeld B, Baird AE, Donnan GA, Jolley D, Lichtenstein M. Spontaneous reperfusion after ischemic stroke is associated with improved outcome. Stroke 1998; 29: 2522-8.
9 Bartenstein P, Ludolph A, Schober O, Lottes G, Scheidhauer K, Sciuk J, Beer H-F. Benzodiazepine receptors and cerebral blood flow in partial epilepsy. Eur J Nucl Med 1991; 18: 111-8.
10 Bartenstein P, Koepp M. Benzodiazepinrezeptor-Darstellung mit Positronen-Emissionstomographie und Single-Photon-Emissionstomographie. Nervenarzt 1995; 66: 412-21.
11 Bartenstein P, Minoshima S, Hirsch C, Buch K, Willoch F, Mösch D, Schad D, Schwaiger M, Kurz A. Quantitative assessment of cerebral blood flow in patients with Alzheimer’s disease by single photon emission computed tomography. J Nucl Med 1997; 38: 1095-101.
12 Bartenstein P, Weindl A, Spiegel S, Boecker H, Wenzel R, Ceballos-Baumann A, Minoshima S, Conrad B. Central motor processing in Huntington’s disease: a positron emission tomography study. Brain 1997; 120: 1553-67.
13 Bartenstein P, Grünwald F, Herholz K, Kuwert T, Tatsch K, Sabri O, Weiller C. Rolle der Positronen-Emissions-Tomographie (PET) und Single-Photon-Emissions-Tomographie (SPECT) bei der sogenannten »Multiple Chemical Sensitivity« (MCS). Nuklearmedizin 1999; 38: 297-301.
14 Berrouschot J, Barthel H, Hesse S, Köster J, Knapp WH, Schneider D. Differentiation between transient ischemic attack and ischemic stroke within the first six hours after onset of symptoms by using Tc-99m-ECDSPECT. J Cereb Blood Flow Metab 1998; 18: 921-9.
15 Berrouschot J, Barthel H, Kummer R, Knapp WH, Hesse S, Schneider D. 99m-Technetiumethyl-cysteinate-dimer single-photon emission CT can predict fatal ischemic brain edema. Stroke 1998; 29: 2556-62.
16 Berrouschot J, Barthel H, Köster J, Hesse S, Rössler A, Knapp WH, Schneider D. Extracorporeal rheopheresis in the treatment of acute ischemic stroke: a randomized pilot study. Stroke 1999; 30: 787-92.
17 Biersack HJ, Reichmann K, Winkler C. et al. 99mTc-labeled hexamethyl-propyleneamine oxime photon emission scans in epilepsy. Lancet 1985; 11: 1436-37.
18 Biersack HJ, Coenen HH, Stocklin G, Reichmann K, Bockisch A, Oehr P, Kashab M, Rollmann O. Imaging of brain tumors with L-3-[123I]iodo-alpha-methyl tyrosine and SPECT. J Nucl Med 1989; 30: 110-2.
19 Boecker H, Kuwert T, Langen KJ, Lange HW, Czech N, Ziemons K, Herzog H, Shikare S, Weindl A, Feinendegen LE. SPECT with HMPAO compared to PET with FDG in Huntington disease. J Comput Assist Tomogr 1994; 18: 542-8.
20 Bohuslavizki KH, Brenner W, Braunsdorf WE, Behnke A, Tinnemeyer S, Hugo H, Jahn N, Wolf H, Sippel C, Clausen M, Mehdorn HM, Henze E. Somatostatin receptor scintigraphy in the differential diagnosis of meningioma. Nucl Med Commun 1996; 17: 302-10.
21 Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, Janssen AG, Stoof JC, van Royen EA. Imaging of dopamine transporters with iodine-123-FP-CITSPECT in healthy controls and patients with Parkinsonsi’s disease. J Nucl Med 1998; 39: 1879-84.
22 Brooks DJ. The earlv diagnosis of Parkinson’s disease. Ann Neurol 1998; 44: S10-8.
23 Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kufferle B, Müller C, Deecke L. Dopamine D2 receptor imaging with SPECT: Studies in different neuropsychiatrie disorders. J Cereb Blood Flow Metabol 1991; 11: 220-8.
24 Brücke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, Müller C, Podreka I. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm 1997; 50 (Suppl) 9-24.
25 Buell U, Braun H, Ferbert A, Stirner H, Weiller C, Ringelstein EB. Combined SPECT imaging of regional cerebral blood flow (99mTc-hexamethyl-propyleneamine oxime, HMPAO) and blood volume (99mTc-RBC) to assess regional cerebral perfusion reserve in patients with cerebrovascular disease. Nuklearmedizin 1988; 27: 51-6.
26 Buell U. PET and SPECT to achieve diagnostic impact. Nuklearmedizin 1990; 29: 71-6.
27 Byrne TN. Imaging of gliomas. Semin Oncol 1994; 21: 162-71.
28 Carvalho PA, Schwartz RB, Alexander 3d E, Garada BM, Zimmerman RE, Loeffler JS, Holman BL. Detection of recurrent gliomas with quantitative thallium-201/technetium-99m HMPAO single-photon emission computerized tomography. J Neurosurg 1992; 77: 565-70.
29 Chang W, Loncaric S, Huang G, Sanpitak P. Asymmetric fan transmission CT on SPECT systems. Phys Med Biol 1995; 40: 913-28.
30 Chiron C, Bulteau C, Loc’h C, Raynaud C, Garreau B, Syrota A, Maziere B. Dopaminergic D2 Receptor SPECT Imaging in Rett Syndrome: Increase of Specific Binding in Striatum. J Nucl Med 1993; 34: 1717-21.
31 Cikrit DF, Burt RW, Dalsing MC, Lalka SG, Sawchuk AP, Waymire B, Witt RM. Acetazolamide enhanced single photon emission computed tomography (SPECT) evaluation of cerebral perfusion before and after carotid endarterectomy. J Vase Surg 1992; 15: 747-53.
32 Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997; 79: 1381-93.
33 Cordes M, Hierholzer J, Schelosky L, Poewe W, Cordes I, Horowski R, Eichstaedt H, Schmidt D, Felix R. IBZM-SPECT Imaging in Parkinson’s disease – Quantification of Binding Ratios from Sequential SPECT Measurements in Patients and Controls. Adv Neurol 1993; 60: 525-8.
34 Costa DC, George MS, Ell PJ, Pilowsky L, Verhoeff NPLG, Robertson MM. Dopamine D2 receptor availability in patients with Gilles de la Tourette syndrome studied with SPET. Nuclear Medicine 1992; Suppl 28: 414-7.
35 Davis SM, Chua MG, Lichtenstein M, Rossiter SC, Binns D, Hopper JL. Cerebral hypoperfusion in stroke prognosis and brain recovery. Stroke 1993; 24: 1691-6.
36 Devous MD, Thisted RA, Morgan GF, Leroy RF, Rowe CC. SPECT brain imaging in epilepsy: a meta-analysis. J Nucl Med 1998; 39: 285-93.
37 Dierckx RA, Martin JJ, Dobbeleir A, Crois R, Neetens I, De Deyn PP. Sensitivity and specificity of thallium-201 single-photon emission tomography in the functional detection and differential diagnosis of brain tumours. Eur J Nucl Med 1994; 21: 621-33.
38 Dong Y, Fukuyama H, Nabatame H, Yamauchi H, Shibasaki H, Yonekura Y. Assessment of benzodiazepine receptors using iodine-123-labeled iomazenil single-photon emission tomography in patients with ischemic cerebrovascular disease. A comparison with PET study. Stroke 1997; 28: 1776-82.
39 Duncan R, Patterson J, Hadley DM. et al. Tc-99m-HMPAO single photon emission computed tomography in temporal lobe epilepsy. Acta Neurol Scand 1990; 81: 287-93.
40 Elger CE, Schramm J. Chirurgische Epilepsietherapie. Radiologe 1993; 33: 165-71.
41 Ericson K, Lilja A, Bergstrom M, Collins VP, Eriksson L, Ehrin E, von Holst H, Lundqvist H, Langsrom BB, Mosskin M. Positron emission tomography with ([11C]methyl)-L-methionine, [UC]D-glucose. and [68Ga]EDTA in supratentorial tumors. J Comput Assist Tomogr 1985; 9: 683-9.
42 Frey JL. Asymptomatic carotid stenosis: Surgery’s the answer, but that’s not the question. Ann Neurol 1996; 39: 405-6.
43 Goodman MM, Kung MP, Kabalka GW, Kung HF, Switzer R. Synthesis and Characterization of Radioiodinated N-(3-Iodopropen-lyl)-2ßcarbomethoxy-3ß-(4-chlorophenyl)tropanes: Potential Dopamine Reuptake Site Imaging Agents. J Med Chem 1994; 37: 1535-42.
44 Grotta JC, Alexandrov AV. rtPA-associated reperfusion after acute stroke demonstrated by SPECT. Stroke 1998; 29: 429-32.
45 Grünwald F, Durwen HF, Bülau P. et al. HMPAO-SPECT bei zerebralen Anfällen. Nuklearmedizin 1988; 27: 248-51.
46 Grünwald F, Durwen HF, Bockisch A. et al. Technetium-99m-HMPAO brain SPECT in medically intractable temporal lobe epilepsy: a postoperative evaluation. J Nucl Med 1991; 32: 388-94.
47 Grünwald F, Menzel C, Pavics L. et al. letal and interictal brain SPECT imaging in epilepsy using Technetium-99m-ECD. J Nucl Med 1994; 35: 1896-901.
48 Guckel FJ, Brix G, Schmiedek P, Piepgras Z, Becker G, Kopke J, Gross H, Georgi M. Cerebrovascular reserve capacity in patients with occlusive cerebrovascular disease: assessment with dynamic susceptibility contrast-enhanced MR imaging and the acetazolamide stimulation test. Radiology 1996; 201: 405-12.
49 Haberl RL, Steiger HJ. Endarterektomie bei asymptomatischen A.-carotis-Stenosen?. Nervenarzt 1996; 67: 177-8.
50 Hanson SK, Grotta JC, Rhoades H, Tran HD, Lamki LM, Barron BJ, Taylor WJ. Value of single-photon emission-tomography in acute stroke therapeutic trials. Stroke 1993; 24: 1322-9.
51 Hashimoto J, Kubo A, Ogawa K, Amano T, Fukuuchi Y, Motomura N, Ichihara T. Scatter and attenuation correction in technetium-99m brain SPECT. J Nucl Med 1997; 38: 157-62.
52 Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RJ, Mendoza G, Weber-Luxenburger G, Lottgen J, Thiel A, Wienhard K, Heiss WD. llC-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998; 50: 1316-22.
53 Hierholzer J, Cordes M, Schelosky L, Sander B, Bock JC, David I, Horowski R, Poewe W. Differentialdiagnose der Parkinson-Erkrankungen – 123I-IBZM-SPECT vs. Apomorphine-Test. Fortschr Röntgenstr 1993; 159: 86-90.
54 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-4.
55 Ichise M, Toyama H, Fornazzari L, Ballinger JR, Kirsh JC. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients at risk for Huntington’s disease. J Nucl Med 1993; 34: 1274-81.
56 Ichise M, Kim YJ, Ballinger JR, Vines D, Erami SS, Tanaka F, Lang AE. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology 1999; 52: 1206-14.
57 Jeon B, Kim JM, Jeong JM, Kim KM, Chang YS, Lee DS, Lee MC. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson’s disease. J Neurol Neurosurg Psychiatry 1998; 65: 60-4.
58 Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M, Kirchner PT. Diagnosis of recurrent brain tumor: value of 201T1 SPECT vs 18F-fluorodeoxyglucose PET. Am J Roentgenol 1994; 163: 1459-65.
59 Karonen JO, Vanninen RL, Liu Y, Ostergaard L, Kuikka JT, Nuutinen J. et al. Combined diffusion and perfusion MRI with correlation to single photon emission CT in acute ischemic stroke. Ischemic penumbra predicts infarct growth. Stroke 1999; 30: 1538-90.
60 Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del-Fiore G, Luxen A, Reznik M. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998; 39: 778-85.
61 Knable MB, Douglas WJ, Coppola R, Hyde TM, Lee KS, Gorey J, Weinberger DR. Lateralized differences in Iodine-123-IBZM uptake in basal ganglia in asymmetric Parkinson’s disease. J Nucl Med 1995; 36: 1216-25.
62 König M, Klotz E, Luka B, Venderink DJ, Spittler JF, Heuser L. Perfusion CT of the brain: diagnostic approach for early detection of ischemic stroke. Radiology 1998; 209: 85-93.
63 Kouris K, Jarritt PH, Costa DC, Ell PJ. Physical assessment of the GE/CGR Neurocam and comparison with a single rotating gammacamera. Eur J Nucl Med 1992; 19: 236-42.
64 Kretschmann HJ, Weinrich W. Neurofunctional Systems; 3D Reconstructions with correlated neuroimaging. Stuttgart: Thieme; 1998
65 Kuji I, Sumiya H, Tsuji S, Ichikawa A, Tonami N. Asymmetries of benzodiazepine receptor binding potential in the inferior medial temporal lobe and cerebellum detected with I-123-iomazenil SPECT in comparison with Tc-99m-HMPAO SPECT in patients with partial epilepsy. Ann Nucl Med 1998; 12: 185-90.
66 Kung HF, Alavi A, Chang W, Kung MP, Keyes Jr. JW, Velchik MG, Billings J, Pan S, Noto R, Rausch A, Reilly J. In vivo SPECT imaging of CNS dopamine D2 receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med 1990; 31: 573-9.
67 Kung MP, Kung HF, Billings J, Yang Y, Murphy RA, Alavi A. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent. J Nucl Med 1990; 31: 648-54.
68 Kung MP, Stevenson DA, Plössl K, Meegalla SK, Beckwith A, Essman WD, Mu M, Lucki I, Kung HF. [99mTc]TRODAT-l : a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med 1997; 24: 372-80.
69 Kuwert T, Sures T, Herzog H, Jansen P, Langen KJ, Loken M, Hennerici M, Feinendegen LE. The influence of image resolution on the positron emission tomographic measurement of caudate glucose consumption. Eur J Nucl Med 1993; 20: 753-8.
70 Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B, Samnick S, Maasjosthusmann U, Lerch H, Gildehaus FJ, Wassmann H, Schober O. Uptake of iodine-123-alpha-methyl tyrosine by gliomas and nonneoplastic brain lesions. Eur J Nucl Med 1996; 23: 1345-53.
71 Kuwert T, Woesler B, Morgenroth C, Lerch H, Schafers M, Palkovic S, Matheja P, Brandau W, Wassmann H, Schober O. Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. J Nucl Med 1998; 39: 23-7.
72 Lamy-Lhullier C, Dubois F, Blond S, Lecouffe P, Steinling M. Importance of cerebral tomoscintigraphy using technetium-labeled sestamibi in the differential diagnosis of current tumor vs. radiation necrosis in subtentorial glial tumors in the adult. Neurochirurgie 1999; 45: 110-7.
73 Langen KJ, Herzog H, Rota E, Roosen N, Wieler H, Kiwit J, Kuwert T, Storch-Becker A, Feinendegen L. Tomographic studies of rCBF with 99mTc-HM-PAO SPECT in comparison with PET in patients with primary brain tumors. Neurosurg Rev 1987; 10: 23-4.
74 Langen KJ, Coenen HH, Roosen N, Kling P, Muzik O, Herzog H, Kuwert T, Stocklin G, Feinendegen LE. SPECT studies of brain tumors with L-3-[123I] iodo-alpha-methyl tyrosine: comparison with PET. 124IMT and first clinical results. J Nucl Med 1990; 31: 281-6.
75 Langen KJ, Ziemons K, Kiwit JC, Herzog H, Kuwert T, Bock WJ, Stocklin G, Feinendegen LE, Muller-Gartner HW. 3-[123I]iodo-alphamethyltyrosine and [methyl-llC]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med 1997; 38: 517-22.
76 Laulumaa V, Kuikka JT, Soininen H, Bergström K, Länsimies E, Riekkinen P. Imaging of D2 Dopamine Receptors of Patients with Parkinson’s Disease using Single Photon Emission Computed Tomography and Iodobenzamide 1123. Arch Neurol 1993; 50: 509-12.
77 Laurin NR, Driedger AA, Hurwitz GA, Mattar AG, Powe JE, Chamberlain MJ, Zabel PL, Pavlosky WF. Cerebral perfusion imaging with technetium-99m HMPAO in brain death and severe central nervous system injury. J Nucl Med 1989; 30: 1627-35.
78 Leeds NE, Jackson E. Current imaging techniques for the evaluation of brain neoplasms. Curr Opin Oncol 1994; 6: 254-61.
79 Leinsinger G, Fürst H, Schmiedek P, Einhäupl K, Kirsch CM. Cerebrovascular reserve capacity measured with 133-Xenon dynamic SPECT before and after carotid endarterectomy. In: Stimulated Cerebral Blood Flow. Experimental Findings and Clinical Significance. Hrsg: Schmiedek P, Einhäupl K, Kirsch CM. Berlin, Heidelberg, New York: Springer Verlag; 1992: 250-6.
80 Lorberboym M, Estok L, Machac J, Germano I, Sacher M, Feldman R, Wallach F, Dorfman D. Rapid differential diagnosis of cerebral toxoplasmosis and primary central nervous system lymphoma by thallium-201 SPECT. J Nucl Med 1996; 37: 1150-4.
81 Lorberboym M, Wallach F, Estok L, Mosesson RE, Sacher M, Kim CK, Machac J. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med 1998; 39: 1366-9.
82 Maffioli L, Gasparini M, Chiti A, Gramaglia A, Mongioj V, Pozzi A, Lombardieri E. Clinical role of technetium-99m sestamibi singlephoton emission tomography in evaluating pretreated patients with brain tumours. Eur J Nucl Med 1996; 23: 308-11.
83 Maraganore DM, O’Connor MK, Bower JH, Kuntz KM, McDonnell SK, Schaid DJ, Rocca WA. Detection of preclinical Parkinson’s disease in at-risk family members with use of [123I]ß-CIT and SPECT: an exploratory study. Mayo Clin Proc 1999; 74: 681-5.
84 Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS, van Dyck C, Hoffer PB, Innis RP. [1231] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 1996; 46: 231-7.
85 Masdeu JC, Brass LM. SPECT imaging of stroke. J Neuroimaging 1995; 5: 14-22.
86 Matheja P, Kuwert T, Stodieck SR, Diehl B, Wolf K, Schuierer G, Ringelstein EB, Schober O. PET and SPECT in medically non-refractory complex partial seizures. Temporal asymmetries of glucose consumption, benzodiazepine receptor density, and blood flow. Nuklearmedizin 1998; 37: 221-6.
87 Matheja P, Rickert C, Weckesser M, Palkovic S, Löttgen J, Riemann B, Kopka K, Kuwert T, Wassmann H, Paulus W, Schober O. Sequential scintigraphic strategy for the differentiation of brain tumours. Eur J Nucl Med 2000; 27: 550-8.
88 Maziere B, Maziere M. Where have we got to with neuroreceptor mapping of the human brain. Eur J Nucl Med 1990; 16: 817-35.
89 Menzel C, Hufnagel A, Grünwald F. et al. The relevance of interictal rCBF brain SPECT in temporal lobe epilepsy: diagnostical value and effects of spatial resolution. Ann Nucl Med 1995; 9: 215-23.
90 Menzel C, Grünwald F, Steidele S. et al. Can secondary activation/inhibition of tracer uptake in partial epilepsy as seen with ictal rCBFSPECT be used to suggest the possible area of seizure onset?. Eur J Nucl Med 1996; 23: 1086
91 Menzel C, Steidele S, Grünwald F, Hufnagel A, Pavics L, Elger CE, Biersack HJ. Evaluation of Technetium-99m-ECD in childhood epilepsy. J Nucl Med 1996; 37: 1106-12.
92 Menzel C. Guidelines for brain perfusion SPECT with technetium-99m radiopharmaceuticals. Nuklearmedizin 1999; 38: 237-9.
93 Minoshima S, Koeppe RA, Mintun MA. Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med 1993; 34: 322-9.
94 Mozley PD, Kim HJ, Gur RC, Tatsch K, Muenz LR, McElgin WT, Kung MP, Mu M, Myers AM, Kung HF. Iodine-123 IPT SPECT Imaging of CNS Dopamine Transporters: Nonlinear Effects of Normal Aging on Striatal Uptake Values. J Nucl Med 1996; 37: 1965-70.
95 Mullan BP, O’Connor MK, Hung JC. Single photon emission computed tomography brain imaging. Neurosurg Clin N Am 1996; 7: 617-51.
96 Nagano N, Sasaki H, Aoyagi M, Hirakawa K. Invasion of experimental rat brain tumor: early morphological changes following microinjection of C6 glioma cells. Acta Neuropathol Berl 1993; 86: 117-25.
97 Nagel JS, Ichise M. Holman BL.The scintigraphic evaluation of Huntington’s disease and other movement disorders using single photon emission computed tomography perfusion brain scans. Semin Nucl Med 1991; 21: 11-23.
98 Neumeyer JL, Wang S, Milius RA, Baldwin RM, Zea-Ponce Y, Hoffer PB, Sybirska E, Al-Tikriti M, Laruelle M, Innis RB. [123I]2βcarboxymethoxy-3β-(4-iodophenyl)tropane (β-CIT): high affinity SPECT radiotracer of monoamine re-uptake sites in brain. J Med Chem 1991; 34: 3144-6.
99 Newton MRE, Berkovic SF, Austin MC, Rowe CC, McKay WJ, Bladin PF. Ictal postictal and interictal single-photon emission tomography in the lateralization of temporal lobe epilepsy. Eur J Nucl Med 1994; 21: 1067-71.
100 Noachtar S, Arnold S, Yousry TA, Bartenstein P, Werhahn KJ, Tatsch K. Ictal technetium-99m ethyl cysteinate dimer single-photon emission tomographic findings and propagation of epileptic seizure activity in patients with extratemporal epilepsies. Eur J Nucl Med 1998; 25: 166-72.
101 O’Brien TJ, So EL, Mullan BP, Hauser MF, Brinkmann BH, Bohnen NI, Hanson D, Cascino GD, Jack CR, Sharbrough FW. Subtraction ictal SPECT co-registered to MRI improves clinical usefulness of SPECT in localizing the surgical seizure focus. Neurology 1998; 50: 445-54.
102 Oder W, Brücke T, Kolleger H. et al. Dopamine D2 receptor binding is reduced in Wilson’s disease: correlation of neurological deficits with striatal 1231-Iodobenzamide binding. J Neural Transm 1996; 103: 1093-103.
103 Oertel WH, Tatsch K, Schwarz J, Trenkwalder C, Scherer J, Weinzierl M, Kirsch CM. Decrease of D2 receptors indicated by 1231-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson’s disease. Ann Neurol 1992; 32: 743-8.
104 Ohnishi T, Yano T, Nakano S, Jinnouchi S, Nagamachi S, Flores LI, Nakahara H, Watanabe K. Acetazolamide challenge and technetium-99m-ECD versus iodine-123-IMP SPECT in chronic occlusive cerebrovascular disease. J Nucl Med 1997; 38: 1463-7.
105 Oku N, Matsumoto M, Hashikawa K, Moriwaki H, Ishida M, Seike Y, Terakawa H, Watanabe Y, Uehara T, Nishimura T. Intraindividual differences between Technetium-99m-HMPAO and Technetium-99m-ECD in the normal medial temporal lobe. J Nucl Med 1991; 38: 1109-111.
106 Packard AB, Roach PJ, Davis RT, Carmant L, Davis R, Riviello J, Holmes G, Barnes PD, O’Tuama LA, Bjornson B, Treves ST. Ictal and interictal Technetium-99m-bicisate brain SPECT in children with refractory epilepsy. J Nucl Med 1996; 37: 1101-6.
107 Paulus W. Tumoren des Nerversystems. In: Pfeiffer J, Schröder JM. (eds). Neuropathologie. Morphologische Diagnostik der Krankheiten des Nervensystems, der Skelettmuskulatur und der Sinnesorgane. Berlin: 1995. Springer; 217-62.
108 Piepgras A, Schmiedek P, Leinsinger G, Haberl RL, Kirsch CM, Einhäupl K. Followup studies of cerebrovascular reserve capacity in patients with cerebrovascular disease. In: Stimulated Cerebral Blood Flow. Experimental Findings and Clinical Significance. Hrsg: Schmiedek P, Einhäupl K, Kirsch CM. Berlin, Heidelberg, New York: Springer Verlag; 1992: 263-7.
109 Pietrzyk U, Herholz K, Fink G, Jacobs A, Mielke R, Slansky I, Wurker M, Heiss WD. An interactive technique for three-dimensional image registration: validation for PET, SPECT. MRI and CT brain studies. J Nucl Med 1994; 35: 2011-8.
110 Pirker W, Asenbaum S, Wenger S, Kornhuber J, Angelberger P, Deeke L, Podreka I, Brücke T. Iodine-123-epidepride-SPECT: studies in Parkinsons’s disease, multiple system atrophy and Huntington’s disease. J Nucl Med 1997; 38: 1711-7.
111 Radau PE, Linke R, Slomka PJ, Tatsch K. Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med 2000; 41: 220-7.
112 Reith W, Heiland S, Forsting M, Fischer M, Sartor K. Diffusionsgewichtete Magnetresonanztomographie: eine vielversprechende MR-Technik zur Früherkennung der zerebralen Ischämie. RÖFO 1997; 166: 133-9.
113 Riemann B, Kuwert T, Schuierer G, Matheja P, Schäfers M, Palkovic S, Wassmann H, Schober O. Nicht-invasives Grading von Gliomen: Ein Vergleich zwischen SPET mit J-123-alpha-Methyl Tyrosin und CT/MRT mit Kontrastmittel. Nuklearmedizin 1998; 37: 38.
114 Rinne JO, Kuikka JT, Bergström KA, Rinne UK. et al. Striatal dopamine transporter in different disability stages of Parkinson’s disease Studie with [123I]ß-CIT SPECT. Parkinsonism & Related Disorders 1995; 1: 47-51.
115 Rowe CC, Berkovic SF, Sia STB. et al. Localisation of epileptic foci with postictal single photon emission computed tomography. Ann Neurol 1989; 26: 660-8.
116 Ruiz A, Ganz WI, Post MJ, Camp A, Landy H, Maliin W, Sfakianakis GN. Use of thallium-201 brain SPECT to differentiate cerebral lymphoma from toxoplasma encephalitis in AIDS patients. Am J Neuroradiol 1994; 15: 1885-94.
117 Sabri O, Ringelstein EB, Hellwig D, Schneider R, Schreckenberger M, Kaiser HJ, Mull M, Buell U. Neuropsychological impairment correlates with hypoperfusion and hypometabolism but not with severity of white matter lesions on MRI in patients with cerebral microangiopathy. Stroke 1999; 30: 556-66.
118 Sasaki M, Ichiya Y, Kuwabara Y, Yoshida T, Fukumara T, Masuda K. Benzodiazepine receptors in chronic cerebrovascular disease: comparison with blood flow and metabolism. J Nucl Med 1997; 38: 1693-8.
119 Saur H-B, Bartenstein P, Oberwittler C, Lerch H, Masur H, Schober O. Vergleichende Untersuchungen mit 99mTc-HMPAO und 1231-IBZM bei extrapyramidalen Erkrankungen. Nuklearmedizin 1994; 33: 184-8.
120 Schelosky L, Hierholzer J, Wissel J, Cordes M, Poewe W. Correlation of clinical response in apomorphine test with D2 receptor status as demonstrated by IBZM-SPECT. Mov Disord 1993; 8: 453-8.
121 Schmiedek P, Piepgras A, Leinsinger G, Einhäupl K, Kirsch CM. Extra-Intracraniell bypass surgery in patients with hemodynamic cerebral ischemia. In: Stimulated Cerebral Blood Flow. Experimental Findings and Clinical Significance. Schmiedek P, Einhäupl K, Kirsch CM. (Hrsg). Berlin, Heidelberg, New York: Springer Verlag; 1992: 257-62.
122 Schober O, Galaske R, Heyer R. Determination of brain death with 123I-IMP and 99mTc-HM-PAO. Neurosurg Rev 1987; 10: 19-22.
123 Schober O, Meyer GJ, Duden C, Lauenstein L, Niggemann J, Muller JA, Gaab MR, Becker H, Dietz H, Hundeshagen H. Amino acid uptake in brain tumors using positron emission tomography as an indicator for evaluating metabolic activity and malignancy. Fortschr Geb Rontgenstr Nuklearmed 1987; 147: 503-9.
124 Schreckenberger M, Sabri O, Mull M, Schwarz M, Thron A, Buell U. Cerebral functionalmorphological match or mismatch in cerebrovascular disease: a comparison of flow-volume SPET, CT findings and doppler sonography. Nucl Med Commun 1998; 19: 23-30.
125 Schreiber WG, Guckel F, Stritzke P, Schmiedek P, Schwartz A, Brix G. Cerebral blood flow and cerebrovascular reserve capacity: estimation by dynamic magnetic resonance imaging. J Cereb Blood Flow Metab 1998; 18: 1143-56.
126 Schulz JB, Klockgether T, Petersen D, Jauch M, Müller-Schauenburg W, Spieker S, Voigt K, Dichgans J. Multiple system atrophy: natural history. MRI morphology, and dopamine receptor imaging with 123I-IBZM SPECT. J Neurol Neurosurg Psychiatry 1994; 57: 1047-56.
127 Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH. 1231-Iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with ‘de novo’ parkinsonism. Neurology 1992; 42: 556-61.
128 Schwarz J, Tatsch K, Vogl T, Kirsch CM, Trenkwalder C, Arnold G, Gasser T, Oertel WH. Marked reduction of striatal dopamine D2 receptors as detecetd by 123IBZM-SPECT in a Wilson’s disease patient with generalized dystonia. Mov Disord 1992; 7: 58-61.
129 Schwarz J, Antonini A, Kraft E, Tatsch K, Vogl T, Kirsch CM, Leenders KL, Oertel WH. Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson’s disease. Neurology 1994; 44: 1079-82.
130 Schwarz. Tatsch K, Gasser T, Pogarell O, Arnold G, Oertel WH. [123]IBZM Binding Predicts Dopaminergic Responsiveness in Patients With Parkinsonism and Previous Dopaminomimetic Therapy. Mov Disord 1997; 12: 898-902.
131 Schwarz J, Tatsch K, Gasser T, Arnold G, Pogarell O, Künig G, Oertel WH. [123]IBZM Binding Compared With Long-Term Clinical Follow Up in Patients With De Novo Parkinsonism. Mov Disord 1998; 13: 16-9.
132 Seibyl JP, Marek KL, Quinlan D. et al. Decreased single-photon emission computed tomographic [123I]ß-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 1995; 38: 589-98.
133 Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med 1998; 39: 1500-8.
134 Shoulson I. Where do we stand on neuroprotection? Where do we go from here?. Mov Disord 1998; 13 (Suppl. 01) 46-8.
135 Soricelli A, Cuocolo A, Varrone A, Discepolo A, Tedeschi E, Mainenti PP, Grivet-Fojaja MR, Covelli EM, Postiglione A, Salvatore M. Technetium-99m-tetrofosmin uptake in brain tumors by SPECT: comparison with thallium-201 imaging. J Nucl Med 1998; 39: 802-6.
136 Spencer SS. The relative contributions of MRI. SPECT. and PET imaging in epilepsy. Epilepsia 1994; 35 (Suppl. 06) 72-89.
137 Stefan H, Bauer J, Feistel H. et al. Regional cerebral blood flow during focal seizures of temporal and frontocentral onset. Ann Neurol 1990; 27: 162-6.
138 Stodilka RZ, Kemp BJ, Prato FS, Nicholson RL. Importance of bone attenuation in brain SPECT quantification. J Nucl Med 1998; 39: 190-7.
139 Stoof JC, Winogrodzka A, van Muiswinkel FL, Wolters EC, Voorn P, Groenewegen HJ, Booij J, Drukarch B. Leads for development of neuroprotective treatment in Parkinson’s disease and brain imaging methods for estimating treatment efficacy. Eur J Pharmacol 1999; 375: 75-86.
140 Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme; 1988
141 Tatsch K, Schwarz J, Oertel WH, Kirsch CM. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson’s syndrome and Wilson’s disease. Nucl Med Commun 1991; 12: 699-707.
142 Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, Fieber RS, Hahn K, Kung HF. Relationship between clinical features of Parkinsonis disease and presynaptic dopamine transporter binding assessed with [I-123]IPT and SPECT. Eur J Nucl Med 1997; 24: 415-21.
143 Tatum WO, Chheda H, Easton TS. SPECT during suggestion of nonepileptic seizures. Epilepsia 1993; 34 (Suppl. 06) 61.
144 Ueda T, Hatakeyama T, Kumon Y, Sakaki S, Uraoka T. Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by initial SPECT. Stroke 1994; 25: 298-303.
145 Ueda T, Sakaki S, Yuh WT, Nochide I, Ohta S. Outcome in acute stroke with successful intra-arterial thrombolysis and predictive value of initial single-photon emission-computed tomography. J Cereb Blood Flow Metab 1999; 19: 99-108.
146 Urbach H, Kurthen M, Klemm E, Grunwald T, van Roost D, Linke DB, Biersack HJ, Schramm J, Elger CE. Amobarbital effects on the posterior hippocampus during the intracarotid amobarbital test. Neurology 1999; 52: 1596-602.
147 van Royen EA, Verhoeff NPLG, Speelman JD, Wolters EC, Kuiper MA, Janssen AGM. Multiple System Atrophy and Progressive Supranuclear Palsy. Diminished Striatal D2 Dopamine Receptor Activity Demonstrated by 123I-IBZM Single Photon Emission Computed Tomography. Arch Neurol 1993; 50: 513-6.
148 van-Royen EA, Verhoeff NP, Meylaerts SA, Miedema AR. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands. J Nucl Med 1996; 37: 1449-51.
149 Verhoeff NP, Buell U, Costa DC, Kirsch G, Lottes G, Moretti JL, Podreka I, Schober O, van-Royen EA. Basics and recommendations for brain SPECT. Task Group ‘Neurology’ of the European Association of Nuclear Medicine. Nuklearmedizin 1992; 31: 114-31.
150 Venz S, Cordes M, Straub HB, Hierholzer J, Schröder R, Richter W, Schmitz B, Meencke H, Felix R. Präoperative Bewertung pharmakoresistenter fokaler Epilepsien mit der J-123-Iomazenil-SPECT. Nuklearmedizin 1994; 33: 189-93.
151 Vick NA, Ciric IS, Eller TW, Cozzens JW, Walsh A. Reoperation for malignant astrocytoma. Neurology 1989; 39: 430-2.
152 Weber W, Bartenstein P, Gross MW, Kinzel D, Daschner H, Feldmann HJ, Reidel G, Ziegler SI, Lumenta C, Molls M, Schwaiger M. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 1997; 38: 802-8.
153 Weckesser M, Hufnagel A, Ziemons K, Grießmeier M, Sonnenberg F, Hackländer T, Langen KJ, Holschbach M, Elger CE. Müller-Gärtner HW. Effect of partial volume correction on muscarinic cholinergic receptor imaging with single-photon emission tomography in patients with temporal lobe epilepsy. Eur J Nucl Med 1997; 24: 1156-61.
154 Weckesser M, Griessmeier M, Schmidt D, Sonnenberg F, Ziemons K, Kemna L, Holschbach M, Langen K, Muller-Gartner H. Iodine-123 alpha-methyl tyrosine single-photon emission tomography of cerebral gliomas: standardised evaluation of tumour uptake and extent. Eur J Nucl Med 1998; 25: 150-6.
155 Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W. 1231-beta-CIT and 123I-IBZM SPECT scanning in levodopanaive Parkinson’s disease. Mov Disord 1998; 13: 438-45.
156 Wieler H, Marohl K, Kaiser KP, Klawki P, Frossler H. Tc-99m HMPAO cerebral scintigraphy. A reliable, noninvasive method for determination of brain death. Clin Nucl Med 1993; 18: 104-9.
157 Wieler H. Single-Photon-Emissions-Computertomographie (SPECT) des Gehirnes. Berlin: Springer; 1995
158 Yune MJ, Lee JD, Ryu YH, Kim DI, Lee BI, Kim SJ. Ipsilateral thalamic hypoperfusion on interictal SPECT in temporal lobe epilepsy. J Nucl Med 1998; 39: 281-5.
159 Zubal IG, Spencer SS, Imam K, Seibyl J, Smith EO, Wisniewski G, Hoffer PB. Difference images calculated from ictal and interictal Technetium-99m-HMPAO SPECT scans of epilepsy. J Nucl Med 1995; 36: 684-9.